Ruthenium-based chemotherapeutics: Are they ready for prime time?

Research output: Contribution to journalShort surveypeer-review

419 Scopus citations


Since the discovery of cis-platinum, many transition metal complexes have been synthesized and assayed for antineoplastic activity. In recent years, ruthenium-based molecules have emerged as promising antitumor and antimetastatic agents with potential uses in platinum-resistant tumors or as alternatives to platinum. Ruthenium compounds theoretically possess unique biochemical features allowing them to accumulate preferentially in neoplastic tissues and to convert to their active state only after entering tumor cells. Intriguingly, some ruthenium agents show significant activity against cancer metastases but have minimal effects on primary tumors. Two ruthenium-based drugs, NAMI-A and KP1019, have reached human clinical testing. This review will highlight the chemical properties, mechanism of action, preclinical data, and early phase clinical results of these two lead ruthenium compounds. Other promising ruthenium agents will also be reviewed with emphasis on the novel ruthenium compound ONCO4417, and DW1/2 that has demonstrated Pim-1 kinase inhibition in preclinical systems. Further development of these and other ruthenium agents may rely on novel approaches including rational combination strategies as well as identification of potential pharmacodynamic biomarkers of drug activity aiding early phase clinical studies.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalCancer chemotherapy and pharmacology
Issue number1
StatePublished - May 2010
Externally publishedYes


  • Chemotherapy
  • KP1019
  • NAMI-A
  • ONCO4417
  • Ruthenium


Dive into the research topics of 'Ruthenium-based chemotherapeutics: Are they ready for prime time?'. Together they form a unique fingerprint.

Cite this